Concordia International Corp. has changed its name to ADVANZ PHARMA Corp. The resolution was voted for by shareholders, and approximately 99.9 per cent of the votes cast were in favor of the change.

It is expected that the limited voting shares of the Company will begin trading under the new name, and that the Company’s stock symbol will change from CXR to ADVZ, on or about December 3, 2018. 

“This is an exciting period for ADVANZ PHARMA, our stakeholders, and all our employees across the globe,” said Graeme Duncan, chief executive officer. “This new corporate identity, and the accompanying rebranding that we are working on, will help define ADVANZ PHARMA as a global pharmaceutical company that is determined to help innovate, shape and grow the specialty, off-patent sector. We will aim to go beyond what we have achieved in the past, and current industry standards, as we look to capitalize on this new start.”

ADVANZ PHARMA represents a refocussed and redefined direction that will build on the Company’s current capabilities, and global footprint across more than 90 countries, so that it can meet the increasingly complex needs of global healthcare systems.